Abstract
To examine the effects of recombinant growth factors in vivo, impaired wound healing was studied in genetically diabetic C57BL/KsJ-db/db mice. Large full-thickness skin wounds made on the backs of these mice exhibited significant delays in the entry of inflammatory cells into the wound, the formation of granulation tissue, and in wound closure when compared to their nondiabetic littermates. Recombinant human platelet-derived growth factor (rPDGFBB, 1 or 10 μg), recombinant human basic fibroblast growth factor (rbFGF, 1 μg), or combinations of both were applied topically to the wounds for 5 to 14 days after wounding. Diabetic mouse wounds treated with rPDGF-BB or rbFGF had many more flbroblasts and capillaries in the wound bed at 10 and 21 days than did wounds treated with the vehicle alone. The animals treated with growth factors also had significantly greater wound closure at 21 days than those treated with the vehicle. Combinations of rPDGF-BB and rbFGF improved all parameters of healing but not to a greater extent than either growth factor alone. The effectiveness of rPDGF-BB and rbFGF suggest that recombinant growth factors may be useful in the treatment of patients with deficient wound repair.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1235-1246 |
| Number of pages | 12 |
| Journal | American Journal of Pathology |
| Volume | 136 |
| Issue number | 6 |
| State | Published - Jun 1990 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Pathology and Forensic Medicine
Cite this
PDGF and FGF stimulate wound healing in the genetically diabetic mouse. / Greenhalgh, David G; Sprugel, Katherine H.; Murray, Mark J.; Ross, Russell.
In: American Journal of Pathology, Vol. 136, No. 6, 06.1990, p. 1235-1246.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - PDGF and FGF stimulate wound healing in the genetically diabetic mouse
AU - Greenhalgh, David G
AU - Sprugel, Katherine H.
AU - Murray, Mark J.
AU - Ross, Russell
PY - 1990/6
Y1 - 1990/6
N2 - To examine the effects of recombinant growth factors in vivo, impaired wound healing was studied in genetically diabetic C57BL/KsJ-db/db mice. Large full-thickness skin wounds made on the backs of these mice exhibited significant delays in the entry of inflammatory cells into the wound, the formation of granulation tissue, and in wound closure when compared to their nondiabetic littermates. Recombinant human platelet-derived growth factor (rPDGFBB, 1 or 10 μg), recombinant human basic fibroblast growth factor (rbFGF, 1 μg), or combinations of both were applied topically to the wounds for 5 to 14 days after wounding. Diabetic mouse wounds treated with rPDGF-BB or rbFGF had many more flbroblasts and capillaries in the wound bed at 10 and 21 days than did wounds treated with the vehicle alone. The animals treated with growth factors also had significantly greater wound closure at 21 days than those treated with the vehicle. Combinations of rPDGF-BB and rbFGF improved all parameters of healing but not to a greater extent than either growth factor alone. The effectiveness of rPDGF-BB and rbFGF suggest that recombinant growth factors may be useful in the treatment of patients with deficient wound repair.
AB - To examine the effects of recombinant growth factors in vivo, impaired wound healing was studied in genetically diabetic C57BL/KsJ-db/db mice. Large full-thickness skin wounds made on the backs of these mice exhibited significant delays in the entry of inflammatory cells into the wound, the formation of granulation tissue, and in wound closure when compared to their nondiabetic littermates. Recombinant human platelet-derived growth factor (rPDGFBB, 1 or 10 μg), recombinant human basic fibroblast growth factor (rbFGF, 1 μg), or combinations of both were applied topically to the wounds for 5 to 14 days after wounding. Diabetic mouse wounds treated with rPDGF-BB or rbFGF had many more flbroblasts and capillaries in the wound bed at 10 and 21 days than did wounds treated with the vehicle alone. The animals treated with growth factors also had significantly greater wound closure at 21 days than those treated with the vehicle. Combinations of rPDGF-BB and rbFGF improved all parameters of healing but not to a greater extent than either growth factor alone. The effectiveness of rPDGF-BB and rbFGF suggest that recombinant growth factors may be useful in the treatment of patients with deficient wound repair.
UR - http://www.scopus.com/inward/record.url?scp=0025359279&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025359279&partnerID=8YFLogxK
M3 - Article
C2 - 2356856
AN - SCOPUS:0025359279
VL - 136
SP - 1235
EP - 1246
JO - American Journal of Pathology
JF - American Journal of Pathology
SN - 0002-9440
IS - 6
ER -